Omeros stock declines after European regulatory setback for Narsoplimab
Omeros shares experienced a decline following a European regulatory setback concerning its drug Narsoplimab. Both Investing.com articles report this event, attributing the stock slide to the regulatory issue.
2 articles from 1 outlet covered this story. The underlying claim is sourced from a press release.
What do all outlets agree on?
1 outlet covered “Omeros stock declines after European regulatory setback for Narsoplimab”. All of them report the following:
- Omeros stock slid
- The reason was a European regulatory setback
- The drug involved is Narsoplimab
Which outlets covered this?
All 2 articles found on this story, grouped by the stance of the piece. Every link goes to the original publisher.
pragmatist2